2026 Q2 Corporate Presentation Upcoming Events Event Database June 10, 2026 Orum to participate in a Hong Kong NDR, co-hosted by HSBC and Mirae Asset Securities June 10, 2026 June 10, 2026 Past Events Featured March 16, 2026 Notice of the 10th Annual General Meeting 2026 March 16, 2026 Webcast Registration March 16, 2026 January 16, 2026 J.P. Morgan Healthcare Conference January 16, 2026 January 16, 2026 December 9, 2025 ASH Annual Meeting December 9, 2025 December 9, 2025 November 25, 2025 Corporate Day Hosted by Mirae Asset November 25, 2025 November 25, 2025 November 12, 2025 UBS Global Healthcare Conference November 12, 2025 November 12, 2025 August 1, 2025 2025 Extraordinary General Meeting August 1, 2025 August 1, 2025 June 4, 2025 NDR (Non-Deal Roadshow) Hosted by Samsung Securities June 4, 2025 June 4, 2025 May 30, 2025 UBS Asian Investment Conference 2025 May 30, 2025 May 30, 2025 May 13, 2025 Samsung Global Investors Conference 2025 May 13, 2025 May 13, 2025 March 28, 2025 2025 9th Annual General Meeting March 28, 2025 March 28, 2025 March 26, 2025 2024 Annual Result Conference Call March 26, 2025 March 26, 2025 March 21, 2025 Orum Therapeutics to Host Fourth Quarter 2024 Earnings Conference Call March 21, 2025 March 21, 2025 November 27, 2024 UBS Asia Healthcare Corporate Day - Hong Kong 2024 November 27, 2024 November 27, 2024 October 6, 2024 Orum Therapeutics to Hold Analyst Day in Korea October 6, 2024 October 6, 2024 September 30, 2024 Orum Therapeutics to Host a Global Media Conference Call for the IPO September 30, 2024 September 30, 2024 March 14, 2023 Orum Therapeutics Announces Three Presentations At AACR 2023 March 14, 2023 March 14, 2023 December 10, 2022 Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151 at ASH 2022 December 10, 2022 December 10, 2022 December 10, 2022 Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151, A First-In-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader For AML, At ASH 2022 December 10, 2022 December 10, 2022 April 8, 2022 Orum Therapeutics Presents Preclinical Data At AACR 2022 Highlighting Novel Dual-Precision Targeted Protein Degrader, ORM-5029, Degrading GSPT1 April 8, 2022 April 8, 2022